摘要
2型糖尿病是常见的慢性疾病之一。二肽基肽酶Ⅳ(DPP-4)是治疗2型糖尿病的新靶点,DPP-4抑制剂是一类新型治疗糖尿病类药物,该类抑制剂能够增强胰高血糖素样多肽-1(GLP-1)及葡萄糖依赖促胰岛素多肽(GIP)的活性,延长其在体内的存活时间,减缓2型糖尿病患者的高血糖症状。近年来DPP-4抑制剂成为研究的热点,本文就其作用机制、构效关系、药效、国内外开发现状及研究进展等进行综述。
TypeⅡ diabetes is one of the most common chronic diseases. Dipeptidyl peptidase Ⅳ（DPP-4） inhibitor is a novel type of drug for the treatment of typeⅡdiabetes, which can enhance glucagon-like peptide-1（GLP-1） and glucose-dependent insulinotropic ploypeptide（GIP） activity in vivo and reduce symptoms of hyperglycemia in patients with typeⅡdiabetes. Nowadays, DPP-4 inhibitors have received growing attention worldwide. In this paper, we reviewed the mechanism, structure-activity relationship, efficacy, development status and research progress in DPP-4 inhibitors.
出处
《中南药学》
CAS
2017年第5期545-553,共9页
Central South Pharmacy
